Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer

References

• National Cancer Institute [webpage on the Internet]SEER Stat Fact Sheets: Bladder Cancer2016 Available from: http://seer.cancer.gov/statfacts/html/urinb.htmlAccessed February 4, 2016
   Google Scholar
• American Cancer SocietyCancer Facts & FiguresAtlanta, GAAmerican Cancer Society2016
   Google Scholar
• SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• Weill Cornell Medical College [webpage on the Internet]Types of Bladder Cancers2015 Available from: https://www.cornellurology.com/clinical-conditions/bladder-cancer/types-of-bladder-cancers/Accessed August 10, 2015
   Google Scholar
• Cancer Research UK [webpage on the Internet]Types of Bladder Cancer2015 Available from: http://www.cancerresearchuk.org/about-cancer/type/bladder-cancer/about/types-of-bladder-cancerAccessed August 12, 2015
   Google Scholar
• KaufmanDSShipleyWUFeldmanASBladder cancerLancet2009374968523924919520422
   PubMed Web of Science ®Google Scholar
• KantorAFHartgePHooverRNFraumeniJFEpidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladderCancer Res19884813385338553378221
   PubMed Web of Science ®Google Scholar
• LottSLopez-BeltranAMontironiRMacLennanGTChengLSoft tissue tumors of the urinary bladder: part II: malignant neoplasmsHum Pathol200738796397717574946
   PubMed Web of Science ®Google Scholar
• KirkaliZChanTManoharanMBladder cancer: epidemiology, staging and grading, and diagnosisUrology2005666 suppl 143416399414
   PubMed Web of Science ®Google Scholar
• ReidLMLeavIKwanPWRussellPMerkFBCharacterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude miceCancer Res19844410456045736467211
   PubMed Web of Science ®Google Scholar
• MallinKDavidKACarrollPRMilowskyMINanusDMTransitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007)J Urol201118551631163621419456
   PubMed Web of Science ®Google Scholar
• YeeDSIshillNMLowranceWTHerrHWElkinEBEthnic differences in bladder cancer survivalUrology201178354454921782222
   PubMed Web of Science ®Google Scholar
• CalleEERodriguezCWalker-ThurmondKThunMJOverweight, obesity, and mortality from cancer in a prospectively studied cohort of US adultsNew Engl J Med2003348171625163812711737
   PubMed Web of Science ®Google Scholar
• QinQXuXWangXZhengXYObesity and risk of bladder cancer: a meta-analysis of cohort studiesAsian Pac J Cancer Prev20131453117312123803089
   PubMedGoogle Scholar
• WyszynskiATanyosSAReesJRBody mass and smoking are modifiable risk factors for recurrent bladder cancerCancer2014120340841424122218
   PubMed Web of Science ®Google Scholar
• VillanuevaCMFernandezFMalatsNGrimaltJOKogevinasMMeta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancerJ Epidemiol Community Health200357316617312594192
   PubMed Web of Science ®Google Scholar
• FerrísJBerbelOAlonso-LópezJGarciaJOrtegaJAEnvironmental non-occupational risk factors associated with bladder cancerActas Urol Esp201337957958623618510
   PubMed Web of Science ®Google Scholar
• MinkPJAlexanderDDBarrajLMKelshMATsujiJSLow-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysisRegul Toxicol Pharmacol200852329931018783726
   PubMed Web of Science ®Google Scholar
• ChuHACrawford-BrownDJInorganic arsenic in drinking water and bladder cancer: a meta-analysis for dose-response assessmentInt J Environ Res Public Health20063431632217159272
   PubMedGoogle Scholar
• BurgerMCattoJWDalbagniGEpidemiology and risk factors of urothelial bladder cancerEur Urol201363223424122877502
   PubMed Web of Science ®Google Scholar
• FreedmanNDSilvermanDTHollenbeckARSchatzkinAAbnetCCAssociation between smoking and risk of bladder cancer among men and womenJAMA2011306773774521846855
   PubMed Web of Science ®Google Scholar
• ChenCHShunCTHuangKHStopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancerBJU Int2007100228128617419696
   PubMed Web of Science ®Google Scholar
• SathiakumarNMacLennanPAMandelJDelzellEA review of epidemiologic studies of triazine herbicides and cancerCrit Rev Toxicol201141S1134
   PubMedGoogle Scholar
• GaertnerRRTheriaultGPRisk of bladder cancer in foundry workers: a meta-analysisOccup Environ Med2002591065566312356924
   PubMed Web of Science ®Google Scholar
• KoutrosSKaragasMFriesenM0118 lifetime occupational exposure to diesel exhaust and bladder cancer among men in New EnglandOccup Environ Med201471suppl 1A75
   Google Scholar
• TravisLBCurtisREGlimeliusBBladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphomaJ Natl Cancer Inst19958775245307707439
   PubMed Web of Science ®Google Scholar
• FletcherOEastonDAndersonKGilhamCJayMPetoJLifetime risks of common cancers among retinoblastoma survivorsJ Natl Cancer Inst200496535736314996857
   PubMedGoogle Scholar
• PavanelloSMastrangeloGPlacidiDCYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancerEur J Epidemiol201025749150020559687
   PubMed Web of Science ®Google Scholar
• NauwelaërsGBellamriMFessardVTureskyRJLangouëtSDNA adducts of the tobacco carcinogens 2-amino-9 H-pyrido [2, 3-b] indole and 4-aminobiphenyl are formed at environmental exposure levels and persist in human hepatocytesChem Res Toxicol20132691367137723898916
   PubMed Web of Science ®Google Scholar
• Bladder Cancer Diagnosis [webpage on the Internet]Bladder Cancer2015 Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-diagnosisAccessed August 10, 2015
   Google Scholar
• TilkiDBurgerMDalbagniGUrine markers for detection and surveillance of non-muscle-invasive bladder cancerEur Urol201160348449221684071
   PubMed Web of Science ®Google Scholar
• FradetYGrossmanHBGomellaLA comparison of hexamineolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter studyJ Urol20071781687317499291
   PubMed Web of Science ®Google Scholar
• KaraogluIvan der HeijdenAGWitjesJAThe role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancerWorld J Urol201432365165924166285
   PubMed Web of Science ®Google Scholar
• GrossmanHBGomellaLFradetYA phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancerJ Urol20071781626717499283
   PubMed Web of Science ®Google Scholar
• KarlATritschlerSStanislausPPositive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?BJU Int2009103448448718793301
   PubMed Web of Science ®Google Scholar
• KimTGriffinJGHolzbeierleinJMSextonWJImaging in localized and advanced bladder cancerManagement of Bladder CancerNew York CitySpringer20155971
   Google Scholar
• de BoerEHarlaarNJTaruttisAOptical innovations in surgeryBr J Surg20151022e56e7225627136
   PubMed Web of Science ®Google Scholar
• UddinMJMarnettLJSynthesis of 5- and 6-carboxy-X-rhodaminesOrg Lett200810214799480118837556
   PubMed Web of Science ®Google Scholar
• CekanovaMUddinMJBartgesJWMolecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivoCancer Prev Res (Phila)20136546647623531445
   PubMed Web of Science ®Google Scholar
• UddinMJCrewsBCBlobaumALSelective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agentsCancer Res20107093618362720430759
   PubMed Web of Science ®Google Scholar
• American Cancer Society [webpage on the Internet]How Is Bladder Cancer Found?2015 Available from: http://www.cancer.org/cancer/bladdercancer/overviewguide/bladder-cancer-overview-diagnosedAccessed August 28, 2015
   Google Scholar
• BlickCGNazirSAMallettSEvaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinicBJU Int20121101849422122739
   PubMed Web of Science ®Google Scholar
• HafeezSHuddartRAdvances in bladder cancer imagingBMC Med201311110423574966
   PubMedGoogle Scholar
• TekesAKamelIImamKDynamic MRI of bladder cancer: evaluation of staging accuracyAm J Roentgenol2005184112112715615961
   PubMed Web of Science ®Google Scholar
• NicolauCBuneschLPeriLAccuracy of contrast-enhanced ultrasound in the detection of bladder cancerBr J Radiol20118410081091109921123306
   PubMed Web of Science ®Google Scholar
• SunMTrinhQDDiagnosis and staging of bladder cancerHematol Oncol Clin North Am2015292205218vii25836929
   PubMed Web of Science ®Google Scholar
• American Cancer Society [webpage on the Internet]Bladder Cancer Staging2014 Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-stagingAccessed August 7, 2015
   Google Scholar
• RouprêtMBabjukMCompératEEuropean guidelines on upper tract urothelial carcinomas: 2013 updateEur Urol20136361059107123540953
   PubMed Web of Science ®Google Scholar
• KhannaCLindblad-TohKVailDThe dog as a cancer modelNat Biotechnol200624910651066
   PubMed Web of Science ®Google Scholar
• Mayo Clinic [webpage on the Internet]Diseases and Conditions: Bladder Cancer2014 Available from: http://www.mayoclinic.org/diseases-conditions/bladder-cancer/basics/risk-factors/con-20027606Accessed August 12, 2014
   Google Scholar
• SolsonaEIborraIRicosJVMonrosJLCasanovaJDumontREffectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followupJ Urol199916141120112310081851
   PubMed Web of Science ®Google Scholar
• Ali-el-DeinBNabeehAel-BazMShamaaSAshamallahASingle-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled studyBr J Urol19977957317359158511
   PubMedGoogle Scholar
• LammDLBlumensteinBACrawfordEDA randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladderN Engl J Med199132517120512091922207
   PubMed Web of Science ®Google Scholar
• HerrHWSchwalbDMZhangZFIntravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trialJ Clin Oncol1995136140414087751885
   PubMed Web of Science ®Google Scholar
• KawaiKMiyazakiJJorakuANishiyamaHAkazaHBacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineCancer Sci20131041222723181987
   PubMed Web of Science ®Google Scholar
• LammDLBCG in perspective: advances in the treatment of superficial bladder cancerEur Urol199527suppl 1287750528
   PubMedGoogle Scholar
• Chemotherapy for Bladder Cancer [webpage on the Internet]Treatment for Bladder Cancer2015 Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-treating-chemotherapyAccessed 12 August, 2015
   Google Scholar
• KanataniANakagawaTKawaiTAdjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancerClin Genitourin Cancer2014132e107e11225456839
   PubMedGoogle Scholar
• CarballidoEMRosenbergJEOptimal treatment for metastatic bladder cancerCurr Oncol Rep201416940425056737
   PubMed Web of Science ®Google Scholar
• DraganYPSargentLXuYDXuYHPitotHCThe initiation-promotion-progression model of rat hepatocarcinogenesisExp Biol Med199320211624
   Web of Science ®Google Scholar
• HenningsHGlickABGreenhalghDACritical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesisExp Biol Med1993202118
   Web of Science ®Google Scholar
• SmithGCareyFABeattieJMutations in APC, Kirstenras, and p53 – alternative genetic pathways to colorectal cancerProc Natl Acad Sci U S A200299149433943812093899
   PubMed Web of Science ®Google Scholar
• McCulloughSHuYLiRBRCA1 in initiation, invasion, and metastasis of breast cancer: a perspective from the tumor microenvironmentManselRFodstadOJiangWMetastasis of Breast Cancer11NetherlandsSpringer20073146
   Google Scholar
• McConkeyDJLeeSChoiWMolecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progressionUrol Oncol201028442944020610280
   PubMed Web of Science ®Google Scholar
• NetworkTCComprehensive molecular characterization of urothelial bladder carcinomaNature2014507749231532224476821
   PubMed Web of Science ®Google Scholar
• MitraAPDatarRHCoteRJMolecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identificationJ Clin Oncol200624355552556417158541
   PubMed Web of Science ®Google Scholar
• SherrCJMcCormickFThe RB and p53 pathways in cancerCancer Cell20022210311212204530
   PubMed Web of Science ®Google Scholar
• AprelikovaOXiongYLiuETBoth p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinaseJ Biol Chem19952703118195181977629134
   PubMed Web of Science ®Google Scholar
• HollsteinMSidranskyDVogelsteinBHarrisCCp53 mutations in human cancersScience1991253501549531905840
   PubMed Web of Science ®Google Scholar
• EsrigDElmajianDGroshenSAccumulation of nuclear p53 and tumor progression in bladder cancerN Engl J Med199433119125912647935683
   PubMed Web of Science ®Google Scholar
• CooperMJHaluschakJJJohnsonDp53 mutations in bladder carcinoma cell linesOncol Res19946125695797787250
   PubMed Web of Science ®Google Scholar
• ZhuHBYangKXieYQLinYWMaoQQXieLPSilencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cellsWorld J Surg Oncol2013112223356234
   PubMed Web of Science ®Google Scholar
• ChatterjeeSJDatarRYoussefzadehDCombined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinomaJ Clin Oncol20042261007101314981105
   PubMed Web of Science ®Google Scholar
• El-DeiryWSTokinoTVelculescuVEWAF1, a potential mediator of p53 tumor suppressionCell19937548178258242752
   PubMed Web of Science ®Google Scholar
• AhmadISansomOJLeungHYExploring molecular genetics of bladder cancer: lessons learned from mouse modelsDis Model Mech20125332333222422829
   PubMed Web of Science ®Google Scholar
• HinataNShirakawaTZhangZRadiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cellsUrol Res200331638739612955365
   PubMedGoogle Scholar
• PavletichNPChambersKAPaboCOThe DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spotsGenes Dev1993712B255625648276238
   PubMed Web of Science ®Google Scholar
• HarmsKLChenXThe functional domains in p53 family proteins exhibit both common and distinct propertiesCell Death Differ200613689089716543939
   PubMed Web of Science ®Google Scholar
• TeufelDPFreundSMBycroftMFershtARFour domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53Proc Natl Acad Sci U S A2007104177009701417438265
   PubMed Web of Science ®Google Scholar
• MizuaraiSYamanakaKKotaniHMutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cellsCancer Res200666126319632616778209
   PubMed Web of Science ®Google Scholar
• PiantinoCBReisSTVianaNIPrima-1 induces apoptosis in bladder cancer cell lines by activating p53Clinics (Sao Paulo)20136829730323644847
   PubMed Web of Science ®Google Scholar
• WangSKonorevEAKotamrajuSJosephJKalivendiSKalyanaramanBDoxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H2O2- and p53-dependent pathwaysJ Biol Chem200427924255352554315054096
   PubMed Web of Science ®Google Scholar
• ZhuXBelmontHJPrice-SchiaviSVisualization of p53264–272/HLA-A* 0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptorJ Immunol200617653223323216493083
   PubMed Web of Science ®Google Scholar
• FishmanMNThompsonJAPennockGKPhase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264–272)/HLA-A* 0201 complex, in patients with advanced malignanciesClin Cancer Res201117247765777521994418
   PubMed Web of Science ®Google Scholar
• StadlerWMLernerSPGroshenSPhase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusJ Clin Oncol201129253443344921810677
   PubMed Web of Science ®Google Scholar
• HanahanDWeinberg RobertAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• van RhijnBWvan der KwastTHVisANFGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinomaCancer Res20046461911191415026322
   PubMed Web of Science ®Google Scholar
• JebarAHHurstCDTomlinsonDCJohnstonCTaylorCFKnowlesMAFGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinomaOncogene200524335218522515897885
   PubMed Web of Science ®Google Scholar
• SunCHChangYHPanCCActivation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladderHistopathology20115871054106321707707
   PubMed Web of Science ®Google Scholar
• van RhijnBWLurkinIRadvanyiFKirkelsWJvan der KwastTHZwarthoffECThe fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rateCancer Res20016141265126811245416
   PubMed Web of Science ®Google Scholar
• MansourAAbdulreheemMElsherbeenyMEGFR expression predicts recurrence in patients undergoing adjuvant chemotherapy for advanced bladder cancerCancer Res20147419 suppl904
   Web of Science ®Google Scholar
• ZhaoJXuWZhangZPrognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysisInt Urol Nephrol2015471879425384433
   PubMed Web of Science ®Google Scholar
• KopparapuPKBoorjianSARobinsonBDExpression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancerAnticancer Res20133362381239023749886
   PubMed Web of Science ®Google Scholar
• TsaiYCYehCHTzenKYTargeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinomaEur J Cancer20134961458146623153706
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• KnowlesMAPlattFMRossRLHurstCDPhosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancerCancer Metastasis Rev2009283–430531620013032
   PubMed Web of Science ®Google Scholar
• CantleyLCNeelBGNew insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathwayProc Natl Acad Sci U S A19999684240424510200246
   PubMed Web of Science ®Google Scholar
• Puzio-KuterAMCastillo-MartinMKinkadeCWInactivation of p53 and Pten promotes invasive bladder cancerGenes Dev200923667568019261747
   PubMed Web of Science ®Google Scholar
• CarayolNVakanaESassanoACritical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cellsProc Natl Acad Sci U S A201010728124691247420616057
   PubMed Web of Science ®Google Scholar
• ZengZSarbassovDDSamudioIJRapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood200710983509351217179228
   PubMed Web of Science ®Google Scholar
• StreeterEHHarrisALAngiogenesis in bladder cancer – prognostic marker and target for future therapySurg Oncol2002111–28510012031871
   PubMed Web of Science ®Google Scholar
• JonesAFujiyamaCBlancheCRelation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell linesClin Cancer Res2001751263127211350893
   PubMed Web of Science ®Google Scholar
• De LucaACarotenutoARachiglioAThe role of the EGFR signaling in tumor microenvironmentJ Cell Physiol2008214355956717894407
   PubMed Web of Science ®Google Scholar
• GravasSBosinakouIKehayasPGiannopoulosAUrinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potentialUrol Int200473217317715331904
   PubMed Web of Science ®Google Scholar
• StachowiakMKMoffettJJoyAPuchaczEFlorkiewiczRStachowiakEKRegulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cellsJ Cell Biol199412712032237929563
   PubMed Web of Science ®Google Scholar
• LiADubeySVarneyMLDaveBJSinghRKIL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesisJ Immunol200317063369337612626597
   PubMed Web of Science ®Google Scholar
• ZhuZShenZXuCInflammatory pathways as promising targets to increase chemotherapy response in bladder cancerMediators Inflamm2012201252869022811589
   PubMed Web of Science ®Google Scholar
• LammDLBacillus Calmette-Guerin immunotherapy for bladder cancerJ Urol1985134140473892050
   PubMed Web of Science ®Google Scholar
• ThompsonRHDongHLohseCMPD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinomaClin Cancer Res20071361757176117363529
   PubMed Web of Science ®Google Scholar
• NajjarYGKirkwoodJMPembrolizumab: pharmacology and therapeutics reviewHematologic20151719
   Google Scholar
• LutzkyJAntoniaSJBlake-HaskinsAA phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumorsPaper presented at: ASCO Annual Meeting Proceedings2014
   Google Scholar
• ChoDCSosmanJASznolMClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)J Clin Oncol201331a4505
   Web of Science ®Google Scholar
• PeggsKSQuezadaSAKormanAJAllisonJPPrinciples and use of anti-CTLA4 antibody in human cancer immunotherapyCurr Opin Immunol200618220621316464564
   PubMed Web of Science ®Google Scholar
• RibasAKeffordRMarshallMAPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaJ Clin Oncol201331561662223295794
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
   PubMed Web of Science ®Google Scholar
• YangJCHughesMKammulaUIpilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJ Immunother200730882518049334
   PubMed Web of Science ®Google Scholar
• WongHCJengEKRhodePRThe IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activityOncoimmunology2013211e2644224404427
   PubMed Web of Science ®Google Scholar
• ToselloA-CMaryFAmiotMBernardAMaryDActivation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretionJ Inflamm19974811327
   Google Scholar
• CioccaDRCalderwoodSKHeat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implicationsCell Stress Chaperones20051028616038406
   PubMed Web of Science ®Google Scholar
• SchmittEGehrmannMBrunetMMulthoffGGarridoCIntracellular and extracellular functions of heat shock proteins: repercussions in cancer therapyJ Leukoc Biol2007811152716931602
   PubMed Web of Science ®Google Scholar
• da Rocha DiasSFriedlosFLightYSpringerCWorkmanPMaraisRActivated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinCancer Res20056523106861069116322212
   PubMed Web of Science ®Google Scholar
• O’Callaghan-SunolCGabaiVLShermanMYHsp27 modulates p53 signaling and suppresses cellular senescenceCancer Res20076724117791178818089808
   PubMed Web of Science ®Google Scholar
• ProiaDASangJHeSSynergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvest New Drugs20123062201220922227828
   PubMed Web of Science ®Google Scholar
• YingWDuZSunLGanetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapyMol Cancer Ther201211247548422144665
   PubMed Web of Science ®Google Scholar
• KamadaMSoAMuramakiMRocchiPBeraldiEGleaveMHsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cellsMol Cancer Ther20076129930817218637
   PubMed Web of Science ®Google Scholar
• MaruyamaRToyookaSToyookaKOAberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological featuresCancer Res200161248659866311751381
   PubMed Web of Science ®Google Scholar
• BertinoEMOttersonGARomidepsin: a novel histone deacetylase inhibitor for cancerExpert Opin Investig Drugs201120811511158
   PubMed Web of Science ®Google Scholar
• SuzukiTTanakaRHamadaSNakagawaHMiyataNDesign, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitorsBioorg Med Chem Lett20102031124112720056538
   PubMed Web of Science ®Google Scholar
• LiDRZhangHPeekESynergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancerJ Urol2015194254755525748177
   PubMed Web of Science ®Google Scholar
• ChenXScapaJLiuDGodbeyWCancer-specific promoters for expression-targeted gene therapy: ran, brms1, and mcm5J Gene Med20161878910127140445
   PubMed Web of Science ®Google Scholar
• KalluriRNeilsonEGEpithelial-mesenchymal transition and its implications for fibrosisJ Clin Invest2003112121776178414679171
   PubMed Web of Science ®Google Scholar
• MaschlerSWirlGSpringHTumor cell invasiveness correlates with changes in integrin expression and localizationOncogene200524122032204115688013
   PubMed Web of Science ®Google Scholar
• ZhuJPanXZhangZGaoJZhangLChenJDownregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cellsCell Signal20122461323133222570869
   PubMed Web of Science ®Google Scholar
• SachsMDRauenKARamamurthyMIntegrin α v and coxsackie adenovirus receptor expression in clinical bladder cancerUrology200260353153612350512
   PubMed Web of Science ®Google Scholar
• TsujiSChenXHancockBPreclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancerMol Ther Oncolytics201631600427119118
   PubMed Web of Science ®Google Scholar
• WangHCaiZYangFEnhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancerUrology2014832508.e13508.e19
   PubMed Web of Science ®Google Scholar
• van der HorstGBosLvan der MarkMTargeting of alpha-V integrins reduces malignancy of bladder carcinomaPLoS One201499e10846425247809
   PubMed Web of Science ®Google Scholar
• MitsuzukaKHandaKSatohMAraiYHakomoriSA specific microdomain (“glycosynapse 3”) controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of α3β1 integrin with CD9J Biol Chem200528042355453555316103120
   PubMed Web of Science ®Google Scholar
• LiCYangZDuYBCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivoClin Cancer Res201420154001401325002124
   PubMed Web of Science ®Google Scholar
• MohammedSIKnappDWBostwickDGExpression of cycloox-ygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladderCancer Res199959225647565010582676
   PubMed Web of Science ®Google Scholar
• RathoreKAlexanderMCekanovaMPiroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitroTransl Res2014164215816824631063
   PubMed Web of Science ®Google Scholar
• ThananRMurataMMaNNuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancerMediators Inflamm2012201216587922577245
   PubMed Web of Science ®Google Scholar
• YuZPestellTGLisantiMPPestellRGCancer stem cellsInt J Biochem Cell Biol201244122144215122981632
   PubMed Web of Science ®Google Scholar
• ChanKSEspinosaIChaoMIdentification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProc Natl Acad Sci U S A200910633140161402119666525
   PubMed Web of Science ®Google Scholar
• MarottaLLAlmendroVMarusykAThe JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24–stem cell–like breast cancer cells in human tumorsJ Clin Invest20111217272321633165
   PubMed Web of Science ®Google Scholar
• DamrauerJSHoadleyKAChismDDIntrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biologyProc Natl Acad Sci U S A201411183110311524520177
   PubMed Web of Science ®Google Scholar
• LiYRogoffHAKeatesSSuppression of cancer relapse and metastasis by inhibiting cancer stemnessProc Natl Acad Sci U S A201511261839184425605917
   PubMed Web of Science ®Google Scholar
• KurtovaAVXiaoJMoQBlocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistanceNature2015517753320921325470039
   PubMed Web of Science ®Google Scholar
• SonpavdeGJonesBSBellmuntJChoueiriTKSternbergCNFuture directions and targeted therapies in bladder cancerHematol Oncol Clin North Am2015292361376x25836940
   PubMed Web of Science ®Google Scholar
• DingJXuDPanCCurrent animal models of bladder cancer: awareness of translatability (review)Exp Ther Med20148369169925120584
   PubMed Web of Science ®Google Scholar
• ErtürkECohenSPriceJBryanGTPathogenesis, histology, and transplantability of urinary bladder carcinomas induced in albino rats by oral administration of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamideCancer Res19692912221922285387262
   PubMed Web of Science ®Google Scholar
• BecciPJThompsonHJStrumJMBrownCCSpornMBMoonRCN-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in C57BL/6× DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoidsCancer Res19814139279327459879
   PubMed Web of Science ®Google Scholar
• OliveiraPPalmeiraCLourençoLLopezCEvaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamineJ Exp Clin Cancer Res200524460916471324
   PubMed Web of Science ®Google Scholar
• LuYLiuPWenWCross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent modelsAm J Transl Res20103182721139803
   PubMed Web of Science ®Google Scholar
• OyasuREpithelial tumours of the lower urinary tract in humans and rodentsFood Chem Toxicol19953397477557557748
   PubMed Web of Science ®Google Scholar
• ZhangZTPakJHuangHYRole of Ha-ras activation in superficial papillary pathway of urothelial tumor formationOncogene200120161973198011360181
   PubMed Web of Science ®Google Scholar
• HeFMoLZhengXYDeficiency of pRb family proteins and p53 in invasive urothelial tumorigenesisCancer Res200969249413942119951992
   PubMed Web of Science ®Google Scholar
• ChengJHuangHZhangZTOverexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growthCancer Res200262144157416312124355
   PubMed Web of Science ®Google Scholar
• ZhangNLiDShaoJWangXAnimal models for bladder cancer: the model establishment and evaluation (Review)Oncol Lett2015941515151925788992
   PubMed Web of Science ®Google Scholar
• TeicherBATumor models for efficacy determinationMol Cancer Ther20065102435244317041086
   PubMed Web of Science ®Google Scholar
• EklundLBryMAlitaloKMouse models for studying angiogenesis and lymphangiogenesis in cancerMol Oncol20137225928223522958
   PubMed Web of Science ®Google Scholar
• BibbyMOrthotopic models of cancer for preclinical drug evaluation: advantages and disadvantagesEur J Cancer200440685285715120041
   PubMed Web of Science ®Google Scholar
• LodillinskyCRodriguezVVauthayLSandesECasabéAEijánAMNovel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancerJ Urol2009182274975519539312
   PubMed Web of Science ®Google Scholar
• CekanovaMRathoreKAnimal models and therapeutic molecular targets of cancer: utility and limitationsDrug Des Devel Ther2014819111921
   PubMed Web of Science ®Google Scholar
• MakIWEvaniewNGhertMLost in translation: animal models and clinical trials in cancer treatmentAm J Transl Res20146211424489990
   PubMed Web of Science ®Google Scholar
• NorrisAMLaingEJValliVECanine bladder and urethral tumors: a retrospective study of 115 cases (1980–1985)J Vet Intern Med1992631451531619591
   PubMed Web of Science ®Google Scholar
• MutsaersAJWidmerWRKnappDWCanine transitional cell carcinomaJ Vet Intern Med200317213614412683611
   PubMed Web of Science ®Google Scholar
• GlickmanLTSchoferFSMcKeeLJReifJSGoldschmidtMHEpidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogsJ Toxicol Environ Health19892844074142593174
   PubMed Web of Science ®Google Scholar
• WellerRWolfAOyejideATransitional cell carcinoma of the bladder associated with cyclophosphamide therapy in a dogJ Amer Anim Hosp Assoc19795733736
   Google Scholar
• BryanJNKeelerMRHenryCJBryanMEHahnAWCaldwellCWA population study of neutering status as a risk factor for canine prostate cancerProstate200767111174118117516571
   PubMed Web of Science ®Google Scholar
• WithrowSJVailDMPageRWithrow and MacEwen’s Small Animal Clinical OncologyElsevier Health Sciences2013
   Google Scholar
• KnappDWGlickmanNWDeNicolaDBBonneyPLLinTLGlickmanLTNaturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancerPaper presented at: Urologic Oncology Seminars and Original Investigations2000
   Google Scholar
• OkajimaEHiramatsuTHiraoKUrinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in dogsCancer Res1981415195819667214364
   PubMed Web of Science ®Google Scholar
• PatronekGJWatersDJGlickmanLTComparative longevity of pet dogs and humans: implications for gerontology researchJ Gerontol A1997523B171B178
   Google Scholar
• HerrHShipleyWBajorinDCancer of the bladderCancer: Principles and Practice of Oncology6th edPhiladelphia, PALippincott Williams & Wilkins200113961418
   Google Scholar
• KnappDWRamos-VaraJAMooreGEDhawanDBonneyPLYoungKEUrinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug developmentILAR J201455110011824936033
   PubMed Web of Science ®Google Scholar
• DillALEberlinLSCostaABMultivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometryChem-A Eur J2011171028972902
   PubMed Web of Science ®Google Scholar
• CekanovaMUddinMJBartgesJWMolecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivoCancer Prev Res201365466476
   PubMed Web of Science ®Google Scholar
• BurgerMCattoJWDalbagniGEpidemiology and risk factors of urothelial bladder cancerEur Urol201363223424122877502
   PubMed Web of Science ®Google Scholar
• MeutenDTumors of the urinary systemMeutenDTumors in Domestic Animals4th edHoboken, NJJohn Wiley & Sons Inc2002509546
   Google Scholar
• OwenLNTNM Classification of Tumours in Domestic AnimalsGenevaWorld Health Organization1980
   Google Scholar
• WalkerMBreiderMIntraoperative radiotherapy of canine bladder cancerVeter Radiol1987286200204
   Web of Science ®Google Scholar
• KnappDWRichardsonRCBottomsGDTeclawRChanTCPhase I trial of piroxicam in 62 dogs bearing naturally occurring tumorsCancer Chemother Pharmacol19922932142181733554
   PubMed Web of Science ®Google Scholar
• KnappDWGlickmanNWWidmerWRCisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancerCancer Chemother Pharmacol200046322122611021739
   PubMed Web of Science ®Google Scholar
• KnappDSchmidtBWidmerWPreliminary results of carboplatin/piroxicam therapy in canine transitional cell carcinomaPaper presented at: Proceedings 17th Veterinary Cancer Society – American College of Veterinary Radiology Conference1997Chicago, IL
   Google Scholar
• DhawanDCraigBAChengLEffects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladderMol Cancer Ther2010951371137720423998
   PubMed Web of Science ®Google Scholar
• LowPSHenneWADoorneweerdDDDiscovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseasesAcc Chem Res200841112012917655275
   PubMed Web of Science ®Google Scholar
• DhawanDRamos-VaraJANaughtonJFTargeting folate receptors to treat invasive urinary bladder cancerCancer Res201373287588423204225
   PubMed Web of Science ®Google Scholar
• HahnNMBonneyPLDhawanDSubcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug developmentJ Urol2012187130230922099988
   PubMed Web of Science ®Google Scholar
• LienKGeorgsdottirSSivanathanLChanKEmmeneggerULow-dose metronomic chemotherapy: a systematic literature analysisEur J Cancer201349163387339523880474
   PubMed Web of Science ®Google Scholar
• SchremppDRChildressMOStewartJCMetronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinomaJ Am Vet Med Assoc2013242111534153823683018
   PubMed Web of Science ®Google Scholar
• CekanovaMUddinMJLegendreAMSingle-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine modelJ Biomed Opt2012171111600211600223117797
   PubMed Web of Science ®Google Scholar
• RathoreKCekanovaMAnimal model of naturally occurring bladder cancer: characterization of four new canine transitional cell carcinoma cell linesBMC Cancer201414146524964787
   PubMedGoogle Scholar
• DhawanDRamos-VaraJAStewartJCZhengRKnappDWCanine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancerUrol Oncol200927328429218562222
   PubMed Web of Science ®Google Scholar
• RamlauRGorbunovaVCiuleanuTEAflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trialJ Clin Oncol201230293640364722965962
   PubMed Web of Science ®Google Scholar
• YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
   PubMed Web of Science ®Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC study 62043)J Clin Oncol200927193126313219451427
   PubMed Web of Science ®Google Scholar
• JordanVCTamoxifen as the first successful targeted therapy in cancer: the gift that kept on givingBreast Cancer Management201434321326
   Google Scholar
• WenPYYungWMellinghoffIKPhase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastomaPaper presented at: ASCO Annual Meeting ProceedingsChicago, IL, USA2014
   Google Scholar
• AngevinEGrunwaldVRavaudAA phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)Paper presented at: ASCO Meet Abstr2011
   Google Scholar
• BendellJCPapadopoulosKJonesSFAbstract B243: a phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumorsMol Cancer Ther20111011 supplB243B243
   Google Scholar
• NordstromJLGorlatovSZhangWAnti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcg receptor binding propertiesBreast Cancer Res201113R12322129105
   PubMed Web of Science ®Google Scholar
• DaviesBThomasonAEllstonR457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamideEur J Cancer20145015024103146
   PubMed Web of Science ®Google Scholar
• KirchnerGIMeier-WiedenbachIMannsMPClinical pharmacokinetics of everolimusClin Pharmacokinet2004432839514748618
   PubMed Web of Science ®Google Scholar
• HidalgoMRowinskyEKThe rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene200019566680668611426655
   PubMed Web of Science ®Google Scholar
• DesaiND’CruzOTrieuVCombination regimens of nabrapamycin (ABI-009) effective against MDA-MB-231 breast-tumor xenograftsCancer Res2009913
   Web of Science ®Google Scholar
• Paper presented at the thirty-Second Annual CTRC-AACR San Antonio Breast Cancer SymposiumDec 10–13, 2009San Antonio, TXCancer Research20096924Supplement
   Google Scholar
• SteinbergGDShoreNKarshLA Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)J ImmunoTherapy Cancer20142suppl 381
   Google Scholar
• XuWJonesMLiuBEfficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myelomaCancer Res201373103075308623644531
   PubMed Web of Science ®Google Scholar
• RibasAHansonDCNoeDATremelimumab (CP-675,206), a cytotoxic T lymphocyte–associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancerOncologist200712787388317673618
   PubMed Web of Science ®Google Scholar
• YangPColemanJLiYSLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancersPaper presented at: CANCER RESEARCH2013
   Google Scholar
• KozłowskaAMackiewiczJMackiewiczATherapeutic gene modified cell based cancer vaccinesGene2013525220020723566846
   PubMed Web of Science ®Google Scholar
• BoniVRixeORascoDAbstract A73: a phase I first-inhuman (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870)Mol Cancer Ther20131211 supplA73A73
   Web of Science ®Google Scholar
• FerrajoliALeeBNSchletteEJLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood2008111115291529718334676
   PubMed Web of Science ®Google Scholar
• GoelSMitaACMitaMA phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res200915124207421219509177
   PubMed Web of Science ®Google Scholar
• MieleESpinelliGPMieleETomaoFTomaoSAlbumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancerInt J Nanomedicine200949919516888
   PubMed Web of Science ®Google Scholar
• RocheMKyriakouHSeidenMDrug evaluation: tesetaxel – an oral semisynthetic taxane derivativeCurr Opin Invest Drugs200671210921099
   PubMedGoogle Scholar
• LattanzioRGhasemiRBrancatiFMembranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancerOncogenesis201439e11825178039
   PubMedGoogle Scholar
• HanadaMMizunoSFukushimaASaitoYNoguchiTYamaokaTA new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complexCancer Sci1998891112291238
   Google Scholar
• HudsonELesterJFGemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literatureEur J Cancer Care2010193324328
   PubMed Web of Science ®Google Scholar
• LanglebenASupkoJGHotteSAbstract LB-171: a phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignanciesCancer Res2010708 supplLB171
   Google Scholar
• IsakoffSOvermoyerBTungNA phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancerJ Clin Oncol20102818S1019
   Google Scholar